30 closest matches · ranked by relevance
Bacterial Vaginosis
Primary: Quantity of BV-associated Bacteria by qPCR and High-throughput Sequencing Tests — 5.59; 5.22; 4.91; 7.41 log10 copies/ml — p=0.011
Contraception
Primary: Number of Participants With Regular Menstrual Cycles — 192; 9; 3; 199 Participants
Menopause Related Conditions · Postmenopausal Symptoms
Primary: Efficacy of VR101 Treatments at 28 Days Assessed by Change in VHI (Vaginal Health Index) Scores Assigned by Clinicians — 1.76; 0.55; 1.38; 0.97 Score on a Scale
Contraception: Optional Applicator for Insertion of Vaginal Ring
Primary: Percentage of Participants With Successful Ring Insertion — 100; 100 Percentage of participants
Human Immunodeficiency Virus (HIV) Prophylaxis
Primary: Number of Participants With Specific Graded Adverse Events in Single, Dual, and Triple Antiretroviral (ARV) Intravaginal Rings (IVRs) — 4; 1; 4; 1 participants
Sexual Dysfunction, Physiological
Primary: Proportion of Participants With Increased Female Sexual Function Index Lubrication Domain (FSFI-LD) Scores — 57; 43 Participants
HIV Infections
Primary: Measurement of TFV Levels in Plasma — 636.8; 1915.9; 3581.5; 5040.7 pg/mL
Contraception
Primary: Changes From Baseline in the Post Coital Test Results (PCT) Due to Device Use. — 0; 26 Participants
Human Immunodeficiency Virus
Primary: The Safety of Dapivirine (25 mg) Administered Via a Silicone Vaginal Ring in HIV-uninfected Adolescent Females, When Inserted Once Every 4 Weeks During 24 Weeks of Study…
HIV
Primary: Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events — 7; 1 Adverse events
Contraception
Primary: Contraceptive Efficacy Using the Pearl Index for All Subjects — 2.96 Number of pregnancies per 100 women mths
HIV-1 Infection
Primary: Etonogestrel Concentrations at Study Day 21 — 1860.00; 429.00; 3290.00 pg/mL — p=<0.001
Human Immunodeficiency Virus
Primary: Safety of Dapivirine (25 mg) Administered in a Silicone Elastomer Vaginal Matrix Ring in HIV-uninfected Postmenopausal Women, When Inserted Once Every 4 Weeks During 12…
Dysmenorrhea
Primary: Change From Baseline in Mean Menstrual Cramping Pain Score Through Cycle 2 — -1.7; -1.7; -1.9; -1.7 Units on a scale — p=< 0.001
Contraceptive Usage · Vaginal Epithelial Disruption
Primary: Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported. — 0.01; -0.005; -0.02; .007 mm
HIV Infections
Primary: Efficacy as Determined by the Proportion of Women in Each Arm With HIV-1 Seroconversion After 120 Endpoints Are Observed in the Trial. — 71; 97 Participants
HIV Infections
Primary: HIV-1 Seroconversion According to Comprehensive HIV Testing Algorithm. — 82; 61 Participants
HIV Infections
Primary: Number of Participants With Grade 2 or Higher Adverse Events (AEs) — 36; 36; 88; 87 Participants — p=0.92
Metrorrhagia
Primary: Mean Number of Bleeding or Spotting Days — 16; 28 days
Birth Control Compliance
Primary: Adherence Rate (Rate of Perfect Method Use) — 57; 45 Percentage of Participants — p=0.05
Contraception
Primary: Percentage of Participants With Ovulation Incidence, by Cycle — 0; 0; 0; 0 Percentage of Participants
HIV Prevention
Primary: The Safety Profile of the 25 mg Dapivirine Vaginal Ring-004, When Inserted at Monthly Intervals. Participants Attended RC at Monthly Visits (up to Max of Three Monthly…
Suppression of Ovulation
Primary: Number of Days Bleeding is Reported. — 34.0; 42.1; 39.8; 14.7 Days
Human Immunodeficiency Virus
Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants
Endometriosis-related Pain
Primary: Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. — -0.66; -2.04; -2.14; -3.68 score on a scale
Recurrent Urinary Tract Infection
Primary: Occurrence of UTI During Randomization — 8; 10 Participants
Pharmacokinetics
Primary: Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol — 1275; 1240; 21.9; 14.8 ng/L
Progesterone Supplementation in Women Undergoing ART
Primary: Cumulative Rate of Spontaneous Abortions Occurring on or Before 12 Weeks Post-oocyte Retrieval — 7.4 percentage of participants
Endometriosis
Primary: Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days…
HIV Infections
Primary: Number of Participants With a Composite Safety Endpoint Adverse Event (AE) — 2; 6; 16; 5 Participants